The HLA System

Total Page:16

File Type:pdf, Size:1020Kb

The HLA System The New England Journal of Medicine Review Articles Advances in Immunology plasmic tail (Fig. 2). There are some 20 class I genes in the HLA region; three of these, HLA-A, B, and C, the so-called classic, or class Ia genes, are the main I AN MACKAY, M.D., AND FRED S. ROSEN, M.D., actors in the immunologic theater. Editors The class II genes code for the a and b polypeptide chains of the class II molecules (Fig. 2). The desig- nation of their loci on chromosome 6 consists of three THE HLA SYSTEM letters: the first (D) indicates the class, the second (M, O, P, Q, or R) the family, and the third (A or B) First of Two Parts the chain (a or b, respectively). HLA-DRB, for ex- ample, stands for class II genes of the R family cod- JAN KLEIN, PH.D., AND AKIE SATO, PH.D. ing for the b chains. The individual genes of the HLA system are differentiated by Arabic numbers, and the notation for the numerous allelic variants of these MAN dies because his body has rejected a genes is a number preceded by an asterisk. For ex- heart transplant; a woman is crippled by rheu- ample, HLA-DRB1*0401 stands for allelic variant A matoid arthritis; a child goes into a coma that 0401 of gene 1, which encodes the b chain of a class is brought on by cerebral malaria; another child dies II molecule belonging to the R family. Each of the of an infection because of an immunodeficiency; an class II a and b chains has four domains: the pep- elderly man has advanced hepatic cirrhosis caused by tide-binding domain (a1 or b1), the immunoglobu- iron overload. These five clinical situations are as di- lin-like domain (a2 or b2), the transmembrane re- verse as can be, yet all have one thing in common: the gion, and the cytoplasmic tail (Fig. 2). cause of all of them involves the human leukocyte an- Class I genes are expressed by most somatic cells, tigen (HLA) system, the human version of the major although the level of expression varies depending on histocompatibility complex (MHC). Malfunction of the tissue.1 By contrast, class II genes are normally ex- the HLA system, which is at the root of these and pressed by a subgroup of immune cells that includes many other clinical disorders, has such wide-ranging B cells, activated T cells, macrophages, dendritic cells, effects not only because of the system’s role in the and thymic epithelial cells.1 In the presence of inter- adaptive immune response, but also because of its feron-g, however, other types of cells can express genetic complexity. class II HLA molecules. The function of both class The HLA complex on chromosome 6 contains over I and class II molecules is the presentation of short, 200 genes, more than 40 of which encode leukocyte pathogen-derived peptides to T cells, a process that antigens (Fig. 1).1-3 The rest are an assortment of genes initiates the adaptive immune response. To under- that are not evolutionarily related to the HLA genes stand this function, it is necessary to place it in the themselves, although some are involved with them context of the cell’s physiology, in particular the proc- functionally.4 Many genes within this complex have ess of waste disposal. nothing to do with immunity. The HLA genes that ANTIGEN PROCESSING are involved in the immune response fall into two AND PRESENTATION classes, I and II, which are structurally and function- ally different (Fig. 2). The class I genes code for the Cells are equipped with an enviably clean and ef- a polypeptide chain of the class I molecule; the ficient system of waste disposal and recycling. A spe- b chain of the class I molecule is encoded by a gene cial molecule, ubiquitin, marks worn-out proteins for dumping (Fig. 3A). These proteins unfold with the on chromosome 15, the beta2-microglobulin gene. The a chain has five domains: two peptide-binding help of other specialized molecules, the chaperones, domains (a1 and a2), one immunoglobulin-like do- and the polypeptide chains are then fed into barrel- main (a3), the transmembrane region, and the cyto- shaped structures, the proteasomes, which chop them up into short fragments.5 The peptides emerging from the proteasome are either degraded into amino acids in the cytosol or transferred into the endoplasmic From the Max-Planck-Institut für Biologie, Abteilung Immungenetik, reticulum. Tübingen, Germany. Address reprint requests to Dr. Klein at the Max-Planck- Extracellular proteins take a different route to deg- Institut für Biologie, Abteilung Immungenetik, Corrensstr. 42, D-72076 Tübingen, Germany, or at [email protected]. radation (Fig. 3B). They are herded into small bags ©2000, Massachusetts Medical Society. that invaginate from the plasma membrane into the 702 · September 7, 2000 The New England Journal of Medicine Downloaded from nejm.org at UC SHARED JOURNAL COLLECTION on May 26, 2011. For personal use only. No other uses without permission. Copyright © 2000 Massachusetts Medical Society. All rights reserved. ADVANCES IN IMMUNOLOGY Chromosome 6 q Centromere p Telomere Telomere Regions 6p21.31 Class II Class III Class I HLA class II% region loci TAPBP PSMB9 (LMP2) TAP1 PSMB8 (LMP1) TAP2 DPB2 DPB1 DPA1 DOA DMA DMB DOB DQB1 DQA1 DRB1 DRB2 DRB3 DRA HLA class III% region loci C21B , a- C4B C4A BF C2 HSPA1B HSPA1A HSPA1L LTB TNF- LTA P450 HLA class I % region loci MICB MICA HLA-B HLA-C HLA-E HLA-A HLA-G HLA-F HFE Figure 1. Location and Organization of the HLA Complex on Chromosome 6. The complex is conventionally divided into three regions: I, II, and III. Each region contains numerous loci (genes), only some of which are shown. Of the class I and II genes, only the expressed genes are depicted. Class III genes are not related to class I and class II genes structurally or functionally. BF denotes complement factor B; C2 complement component 2; C21B cytochrome P-450, subfamily XXI; C4A and C4B complement components 4A and 4B, respectively; HFE hemochromatosis; HSP heat-shock protein; LMP large multifunctional protease; LTA and LTB lymphotoxins A and B, respectively; MICA and MICB major-histocompatibility- complex class I chain genes A and B, respectively; P450 cytochrome P-450; PSMB8 and 9 proteasome b 8 and 9, respectively; TAP1 and TAP2 transporter associated with antigen processing 1 and 2, respectively; TAPBP TAP-binding protein (tapasin); TNF-a tumor necrosis factor a; and HSPA1A, HSPA1B, and HSPA1L heat-shock protein 1A A-type, heat-shock protein 1A B-type, and heat-shock protein 1A–like, respectively. cytoplasm. The bags are then pinched off as endocyt- originating from the pathogen are also routed into ic vesicles, and they fuse with primary lysosomes, the processing pathways. With the exception of jawed which are loaded with an assortment of proteolytic vertebrates, no organisms appear to make a distinction enzymes, to form endosomes.5 Within the endo- between peptides derived from their own (self) pro- somes, the ingested proteins are degraded, first to teins and those derived from foreign (nonself) pro- peptides and then, in some vesicles, into amino acids teins. Jawed vertebrates, by contrast, use the peptides for reuse. derived from foreign (usually microbial) proteins to This mode of protein processing must have evolved mark infected cells for destruction. at an early stage in the history of living forms. Later, In an uninfected cell, “housekeeping” proteasomes the jawed vertebrates found a new use for it by en- continuously churn out self peptides, some of which listing it in the defense of the body against patho- are picked up by molecules called “transporters asso- gens. Normally, the proteins that undergo recycling ciated with antigen processing,” or TAPs, encoded by are the organism’s own, but in infected cells, proteins the TAP1 and TAP2 genes.5 The TAP1 and TAP2 Volume 343 Number 10 · 703 The New England Journal of Medicine Downloaded from nejm.org at UC SHARED JOURNAL COLLECTION on May 26, 2011. For personal use only. No other uses without permission. Copyright © 2000 Massachusetts Medical Society. All rights reserved. The New England Journal of Medicine way to the luminal surface of the endoplasmic retic- Class I Class II ulum. There, the emerging chains are attended by a Peptide-binding? suite of molecular chaperones — calnexin, calreticu- groove lin, endoplasmic reticulum p57, TAP-binding pro- tein (also referred to as tapasin), and perhaps others a2 a1 — which ensure that the polypeptides do not fold a1 b1 prematurely, that they are properly glycosylated, that the a chain meets beta2-microglobulin at the appro- priate time, and that when this moment comes, the union proceeds without a hitch. A class I molecule a b a b a3 b2m 2 2 is then pinioned by the TAP-binding protein to the TAP molecule for loading. When a suitable peptide emerges from the TAP channel, the peptide-binding groove (Fig. 2) of the waiting class I molecule snags TM TM TM it. The loaded molecule then undocks from the com- plex of TAP-binding protein and TAP and sets off Plasma? on a journey to the surface of the cell. There, the membrane class I molecule remains anchored in the plasma mem- Cytoplasmic? Cytoplasmic? brane by the transmembrane region of the a chain. tail tail In this position, it displays the bulk of the a chain (the a1, a2, and a3 domains shown in Fig. 2), the peptide, and the associated beta2-microglobulin to Figure 2. Structure of HLA Class I and Class II Molecules.
Recommended publications
  • MCB 50 Immunity and Disease Lecture Outline MHC Restriction Jan
    MCB 50 Immunity and Disease Lecture Outline MHC Restriction Jan. 31, 2001 I. Definition of self MHC restriction; MHC restriction is the requirement that APC or target cells express MHC molecules that the T cell recognizes as self in order for T cell to respond to the antigen presented by that APC or target cell. (T cells will only recognize antigens presented by their own MHC molecules.) CD8 T cells bind class I MHC which are expressed on most cells in the body. CD4 T cells bind class II MHC which are only expressed on specialized APCs. APCs primarily reside in 2 ° lymphoid tissue (lymph nodes, spleen) but can be found in most tissues. II. MHC Genetics Mouse MHC gene complex called H-2. Human MHC gene complex called HLA. MHC Molecules Mouse H-2 Human HLA Class I K,D,L A, B, C Class II I-A, I-E DR, DQ, DP Definitions: Alleles functional forms of the same genes. Heterozygous different allele at each locus. Homozygous same allele at each locus. Haplotype is the total set of MHC alleles present on one chromosome. For each MHC gene locus you have 2 copies which can be denoted by their allele classification. Most humans will be heterozygous and will have different alleles for each of the different HLA loci. (e.g. A2/A12, B17/B83, C3/C37, DR3/DR4 etc). Syngeneic identical at all MHC loci same allele on both chromosomes. (inbred mice or identical twins). Allogeneic --genetically different at MHC different alleles. Every person gets a chromosome from each biological parent which contains an MHC molecule at each locus.
    [Show full text]
  • Repertoire Selection from Data on the Mature T Cell Deriving Quantitative
    Deriving Quantitative Constraints on T Cell Selection from Data on the Mature T Cell Repertoire This information is current as Vincent Detours, Ramit Mehr and Alan S. Perelson of October 2, 2021. J Immunol 2000; 164:121-128; ; doi: 10.4049/jimmunol.164.1.121 http://www.jimmunol.org/content/164/1/121 Downloaded from References This article cites 75 articles, 24 of which you can access for free at: http://www.jimmunol.org/content/164/1/121.full#ref-list-1 Why The JI? Submit online. http://www.jimmunol.org/ • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average by guest on October 2, 2021 Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2000 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. Deriving Quantitative Constraints on T Cell Selection from Data on the Mature T Cell Repertoire1 Vincent Detours,*†‡ Ramit Mehr,§ and Alan S. Perelson2* The T cell repertoire is shaped in the thymus through positive and negative selection. Thus, data about the mature repertoire may be used to infer information on how TCR generation and selection operate.
    [Show full text]
  • High-Allelic Variability in HLA-C Mrna Expression: Association with HLA-Extended Haplotypes
    Genes and Immunity (2014) 15, 176–181 & 2014 Macmillan Publishers Limited All rights reserved 1466-4879/14 www.nature.com/gene ORIGINAL ARTICLE High-allelic variability in HLA-C mRNA expression: association with HLA-extended haplotypes F Bettens1,2, L Brunet1,2 and J-M Tiercy1 Human leukocyte antigen (HLA)-C is a clinically relevant transplantation antigen in unrelated hematopoietic stem cell and cord blood transplantation. Furthermore, HLA-C antigens, as ligands for killer immunoglobulin-like receptors expressed on natural killer cells, have a central role in HIV control. Several studies have reported significant correlations between HLA-C mRNA and cell surface expression with polymorphisms in the 50- and 30-regions of the HLA-C locus. We determined HLA-C mRNA in blood donors by using locus as well as allele-specific real-time–PCR and focused the analysis on HLA-extended haplotypes. High inter-individual variability of mRNA expression was disclosed. A lower inter-individual variability for C*07:01 but a higher variability for C*06:02, C*04:01 and C*03:04 alleles were detected. The previously reported associations between HLA-C cell surface expression and À 32 kb/ À 35 kb single nucleotide polymorphisms were not confirmed. Related and unrelated individuals sharing the same two A-B-C-DRB1 or B-C haplotypes show strikingly similar levels of HLA-C mRNA expression in each of the different haplotypic combinations tested. Altogether, our results suggest that HLA-C expression levels best correlate with the extended HLA haplotype rather than with the allotype or with polymorphisms in the 50-region of the HLA-C locus.
    [Show full text]
  • Thymic Nurse Cells Participate in Heterotypic
    Send Orders for Reprints to [email protected] 828 Current Molecular Medicine 2015, 15, 828-835 Thymic Nurse Cells Participate in Heterotypic Internalization and Repertoire Selection of Immature Thymocytes; Their Removal from the Thymus of Autoimmune Animals May be Important to Disease Etiology J.C. Guyden1, M. Martinez2, R.V.E. Chilukuri1, V. Reid3, F. Kelly4 and M.-O.D. Samms*,1 1Department of Biology, The City College of New York, New York, NY 10031, USA 2Department of Biology College of Arts and Sciences, Tuskegee University, Armstrong Hall, Room 107, 1200 West Montgomery Road, Tuskegee, AL 36088, USA 3The Hall Perrine Cancer Center, Department of Surgery, Mercy Medical Center Cedar Rapids, IA, Division of Surgical Oncology & Endocrine Surgery, The University of Iowa Hospitals & Clinics, 200 Hawkins Dr, Iowa City, IA 52242, USA 4Essential Health, St Mary’s Medical Center, 407 East 3rd Street, Duluth, MN 55805, USA M.-O.D. Samms Abstract: Thymic nurse cells (TNCs) are specialized epithelial cells that reside in the thymic cortex. The initial report of their discovery in 1980 showed TNCs to contain up to 200 thymocytes within specialized vacuoles in their cytoplasm. Much has been reported since that time to determine the function of this heterotypic internalization event that exists between TNCs and developing thymocytes. In this review, we discuss the literature reported that describes the internalization event and the role TNCs play during T cell development in the thymus as well as why these multicellular complexes may be important in inhibiting the development of autoimmune diseases. Keywords: Thymic nurse cells, internalization, MHC restriction, lupus erythromatosus.
    [Show full text]
  • HLA-Restricted, Processing- and Metabolism-Independent Pathway of Drug Recognition by Human Alpha Beta T Lymphocytes
    HLA-restricted, processing- and metabolism-independent pathway of drug recognition by human alpha beta T lymphocytes. M P Zanni, … , S Valitutti, W J Pichler J Clin Invest. 1998;102(8):1591-1598. https://doi.org/10.1172/JCI3544. Research Article T cell recognition of drugs is explained by the hapten-carrier model, implying covalent binding of chemically reactive drugs to carrier proteins. However, most drugs are nonreactive and their recognition by T cells is unclear. We generated T cell clones from allergic individuals specific to sulfamethoxazole, lidocaine (nonreactive drugs), and cef-triaxone (per se reactive beta-lactam antibiotic) and compared the increase of intracellular free calcium concentration ([Ca2+]i) and the kinetics of T cell receptor (TCR) downregulation of these clones by drug-specific stimulations. All drugs tested induced an MHC-restricted, dose- and antigen-presenting cell (APC)-dependent TCR downregulation on specific CD4(+) and CD8(+) T cell clones. Chemically nonreactive drugs elicited an immediate and sustained [Ca2+]i increase and a rapid TCR downregulation, but only when these drugs were added in solution to APC and clone. In contrast, the chemically reactive hapten ceftriaxone added in solution needed > 6 h to induce TCR downregulation. When APC were preincubated with ceftriaxone, a rapid downregulation of the TCR and cytokine secretion was observed, suggesting a stable presentation of a covalently modified peptide. Our data demonstrate two distinct pathways of drug presentation to activated specific T cells. The per se reactive ceftriaxone is presented after covalent binding to carrier peptides. Nonreactive drugs can be recognized by specific alphabeta+ T cells via a nonconventional presentation pathway based on a labile binding […] Find the latest version: https://jci.me/3544/pdf HLA-restricted, Processing- and Metabolism-independent Pathway of Drug Recognition by Human ab T Lymphocytes Martin P.
    [Show full text]
  • HLA-DPB1 Gene Major Histocompatibility Complex, Class II, DP Beta 1
    HLA-DPB1 gene major histocompatibility complex, class II, DP beta 1 Normal Function The HLA-DPB1 gene provides instructions for making a protein that plays a critical role in the immune system. The HLA-DPB1 gene is part of a family of genes called the human leukocyte antigen (HLA) complex. The HLA complex helps the immune system distinguish the body's own proteins from proteins made by foreign invaders such as viruses and bacteria. The HLA complex is the human version of the major histocompatibility complex (MHC), a gene family that occurs in many species. The HLA-DPB1 gene belongs to a group of MHC genes called MHC class II. MHC class II genes provide instructions for making proteins that are present on the surface of certain immune system cells. These proteins attach to protein fragments (peptides) outside the cell. MHC class II proteins display these peptides to the immune system. If the immune system recognizes the peptides as foreign (such as viral or bacterial peptides), it triggers a response to attack the invading viruses or bacteria. The protein produced from the HLA-DPB1 gene attaches (binds) to the protein produced from another MHC class II gene, HLA-DPA1. Together, they form a functional protein complex called an antigen-binding DPab heterodimer. This complex displays foreign peptides to the immune system to trigger the body's immune response. Each MHC class II gene has many possible variations, allowing the immune system to react to a wide range of foreign invaders. Researchers have identified hundreds of different versions (alleles) of the HLA-DPB1 gene, each of which is given a particular number (such as HLA-DPB1*03:01).
    [Show full text]
  • HLA on Chromosome 6: the Story Gets Longer and Longer Leslie J
    COMMENTARY HLA on Chromosome 6: The Story Gets Longer and Longer Leslie J. Raffel,1 Janelle A. Noble,2 and Jerome I. Rotter1 within the MHC has played a substantial role in allowing disease linkages and associations to be detected. The early ver the past three decades, substantial progress studies that reported associations with HLA-B8 and -B15 has been made in understanding the genetic used remarkably small numbers of cases and controls basis for diabetes. One of the important first relative to the hundreds to thousands considered neces- Osteps that allowed this progress to occur was sary in current studies (4–6). Had it not been for the realizing that diabetes is heterogeneous, and, therefore, strong LD, those initial studies would have been unlikely separation of clinically distinct forms of the disorder (i.e., to yield positive results. Yet, at the same time, this LD has type 1 vs. type 2 diabetes) improves the ability to detect also created challenges in accomplishing the next step, genetic associations. The key points that allowed type 1 that of identification of the specific genes that are respon- diabetes to be separated from type 2 diabetes included sible for disease susceptibility. The fact that researchers realization of the clinical differences (typically childhood have spent Ͼ30 years trying to elucidate all of the loci onset, thin, ketosis-prone versus adult onset, obese, non- responsible for type 1 diabetes susceptibility in the HLA ketosis prone); family and twin studies that demonstrated region underscores the complexity
    [Show full text]
  • A Second Lineage of Mammalian Major Histocompatibility Complex Class I Genes SEIAMAK BAHRAM*, MAUREEN BRESNAHAN*, DANIEL E
    Proc. Nati. Acad. Sci. USA Vol. 91, pp. 6259-6263, July 1994 Immunology A second lineage of mammalian major histocompatibility complex class I genes SEIAMAK BAHRAM*, MAUREEN BRESNAHAN*, DANIEL E. GERAGHTYt, AND THOMAS SPIES* *Diision of Tumor Virology, Dana-Farber Cancer Institute, Harvard Medical School, 44 Binney Street, Boston, MA 02115; and tHuman Immunogenetics Program, Fred Hutchinson Cancer Research Center, 1124 Columbia Street, Seattle, WA 98104 Communicated by Sherman M. Weissman, January 3, 1994 ABSTRACT Major sctibit complex (MHC) polymorphic antigen-presenting molecules (2). The physio- class I genes tpically encode polymorphic peptide-binding logical roles of HLA-E and -F are uncertain (14, 15), but chains which are ubi ly expressed and mediate the HLA-G may have a specific function at the maternal-fetal recognition of intr rtigens by cytotoxic T cells. They interface (16). In addition, the MHC contains a number of constte diverse gene fme in different species and include class I pseudogenes and gene fragments (17); however, all of the numerous cd n acal genes in the mouse H-2 the human class I sequences share close relationships indi- coplex, of which some have been adapted to variously mod- cating their common origin from a typical class I gene. ified hmctions. We have identified a d nt family of five In this report, we describe a family of sequencest in the related sequenes in the human MHC whicb are distntly human MHC which are highly divergent from al of the homologous to dass I i. These MIC genes (MHC class I known MHC class I chains and have presumably been chain-related genes) evolved in parallel with the human class I derived early in the evolution of mammalian class I genes.
    [Show full text]
  • Histocompatibility Antigens
    HISTOCOMPATIBILITY ANTIGENS 2 CRAIG 1. TAYLOR 1 and PHILIP A. DYER Cambridge and Manchester Keratoplasty is a well-established method for the are similar for corneal grafts and other forms of treatment of irreversible corneal opacity, ocular allotransplantation.12,13 disease and injury. For primary transplants in patients with avascular corneal beds (usually asso­ HLA SYSTEM ciated with keratoconus) success rates are relatively The dominant antigenic stimulus for allograft rejec­ high when compared with other forms of organ tion and antibody production is the MHC (major transplantation, with 90-95% 1 year graft survival. I histocompatibility complex). In humans this is known This is achieved even in the absence of intensive as the HLA (human leucocyte antigen) system, The systemic immunosuppression, reflecting the view that products of the MHC genes control T cell antigen the avascular cornea enjoys some degree of recognition. Evidence that HLA is the human MHC 'immunological privilege'. However, even in this came from early kidney transplants performed using situation some 10% of patients undergo a rejection related donors. Graft survival was shown to correlate episode of which up to half may progress to with the number of HLA haplotypes shared between irreversible clouding and graft failure?,3 the donor and recipient, with 90% 1 year graft In contrast, for patients with a vascularised corneal survival between HLA-identical siblings. The 10% of bed a different picture emerges, with 35% graft loss transplant failures despite immunosuppression, is in the first year following transplantation.4 This thought to represent multiple minor histocompat­ ibility antigen differences. situation is more closely analogous to solid organ The HLA system is a complex mUltigene family transplants where vascularisation enables access of consisting of more than 10 loci coded for on the short the host immune system, with a concomitant arm of chromosome 6.
    [Show full text]
  • Biological Consequences of Major Histocompatibility Class-II Expression by Tumor Cells in Cancer
    Author Manuscript Published OnlineFirst on November 21, 2018; DOI: 10.1158/1078-0432.CCR-18-3200 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Biological Consequences of Major Histocompatibility Class-II Expression by Tumor Cells in Cancer Running Title: Biological Consequences of MHC-II Expression by Tumor Cells Margaret L. Axelrod1,2, Rebecca S. Cook2,3,4,5, Douglas B. Johnson1,5, and Justin M. Balko*1,2,5 Affiliations: Department of Medicine, Vanderbilt University Medical Center1; Cancer Biology Graduate Program2, Department of Cell and Developmental Biology3, and Department of Biomedical Engineering4, Vanderbilt University, and the Vanderbilt-Ingram Cancer Center5, Nashville, TN 37232 Acknowledgments: This article is supported by the U.S. Department of Defense (BC170037; J. M. Balko) and the National Institute of General Medical Sciences (T32GM007347; M. L. Axelrod). Conflicts and Disclosures: D. B. Johnson reports receiving commercial research grants from Bristol-Myers Squibb and Incyte, is a consultant/advisory board member for Array, Bristol-Myers Squibb, Genoptix, Merck, Incyte, and Novartis, and is inventor on a provisional patent on the use of MHC-II as a biomarker of immunotherapy response. J. M. Balko is a consultant/advisory board member for Novartis, reports receiving commercial research grants from Incyte, Bristol- Myers Squibb, and Genentech, and is inventor on a provisional patent on the use of MHC-II as a biomarker of immunotherapy response and a patent on HLADR as a biomarker for ICI response. No potential conflicts of interest were disclosed by the other authors. Downloaded from clincancerres.aacrjournals.org on October 2, 2021.
    [Show full text]
  • Orientation of Loci Within the Human Major Histocompatibility Complex by Chromosomal in Situ Hybridization (Human Leukocyte Antigen/Gene Mapping) CYNTHIA C
    Proc. Nati. Acad. Sci. USA Vol. 81, pp. 2816-2820, May 1984 Genetics Orientation of loci within the human major histocompatibility complex by chromosomal in situ hybridization (human leukocyte antigen/gene mapping) CYNTHIA C. MORTON*t, ILAN R. KIRSCHt, WALTER E. NANCE*, GLEN A. EVANS§, ALAN J. KORMAN¶, AND JACK L. STROMINGER¶ *Department of Human Genetics, Medical College of Virginia, Virginia Commonwealth University, Richmond, VA 23298; tNational Cancer Institute, Navy Medical Oncology Branch, The National Naval Medical Center, Building 1, Room 415, Bethesda, MD 20814; §The Cancer Biology Laboratory, The Salk Institute, San Diego, CA 92138; and ¶Fairchild Biochemistry Building, Harvard University, 7 Divinity Avenue, Cambridge, MA 02138 Contributed by Jack L. Strominger, December 29, 1983 ABSTRACT We have determined the localization and ori- with closely linked markers such as glyoxylase 1 (GLO 1) entation of two genetic probes within the human major histo- have permitted inferences to be drawn about the order and compatibility complex by chromosomal in situ hybridization. map distances between marker loci on the proximal portion Our data indicate that a cloned genomic probe cross-hybridiz- of the short arm of chromosome 6, as follows: GLO 1-4 ing to HLA-A, -B, and -C heavy chain loci is homologous to centimorgans (cM)-HLA-DR-0.3 cM-BF, C4B, C4A, sequences located on chromosome 6 at band p21.3 while a sub- C2-0.7 cM-HLA-B-0.1 cM-HLA-C-0.7 cM-HLA-A clone of the genomic HLA-DR a-chain gene corresponding to (16-18). the nonpolymorphic p34 protein is homologous to sequences in Improvements in chromosomal in situ hybridization have band 6p21.1.
    [Show full text]
  • T Cell Maturation
    T-cell Maturation T cell maturation What allows T cell maturation? T cell progenitor DN DP SP 2ry • Direct contact with thymic epithelial cells (Subcapsular (Cortex) (Medulla) lymphoid zone) organs • Influence of thymic hormones THYMUS • Growth factors (cytokines, CSF) The earliest T cell precursors in the thymus : - Express Thy-1 (mice) - Have not yet rearranged TCR loci - Do NOT express CD4 or CD8 - Do not express CD3 - Are called “double negatives” MARKERS: - C-KIT - Receptor for Stem Cell Growth Factor - CD44 - Adh. Molecule. Homing to thymus - CD25 - Alpha chain of IL-2 receptor Time Course of Appearance in Thymus - Most double negative thymocytes will give rise to αβαβαβ T cells (in mice and humans). * - Some (5%) will differentiate into γδγδγδ T cells. - The developmental pathway of γδγδγδ T cells is not well defined. 1 Why is Pre-TCR important? - CD3 expression first appear between DN2 to DN3 - Double negative thymocytes (DN3 stage) undergo β chain locus re-arrangement. - The newly formed β chain combines with the Pre-Tα (surrogate chain) and CD3 to form the Pre-T cell receptor ( Pre-TCR ). 1) Productive TCR β chain re-arrangement 2) Signals for proliferation (similar β chain) and maturation 3) Suppresses further β chain re-arrangement (allelic exclusion) 4) Signals for TCR ααα chain re-arrangement 4) Induces development of CD4+8+ (double positive) stage - After β chain re-arrangement is completed the DN3 cells Positive and Negative selection of T cells: GOAL—to progress to DN4. recognize foreign Ag combined with self MHC - Both CD4 and CD8 are expressed = double positive (DP) cells.
    [Show full text]